Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.

Tytuł :
Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
Autorzy :
Behl T; Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.
Kaur I; Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.
Fratila O; Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410073, Romania.
Brata R; Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410073, Romania.
Bungau S; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea 410028, Romania.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Oct 09; Vol. 21 (20). Date of Electronic Publication: 2020 Oct 09.
Typ publikacji :
Journal Article; Review
Język :
English
Imprint Name(s) :
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms :
Drug Discovery*
Molecular Targeted Therapy*
Alzheimer Disease/*metabolism
Amyloid beta-Peptides/*antagonists & inhibitors
Amyloid beta-Peptides/*metabolism
Alzheimer Disease/drug therapy ; Alzheimer Disease/etiology ; Alzheimer Disease/pathology ; Amyloid beta-Protein Precursor/metabolism ; Animals ; Combined Modality Therapy ; Disease Susceptibility/immunology ; Humans ; Inflammation ; Models, Biological ; Oxidative Stress ; Protein Aggregates ; Protein Aggregation, Pathological
References :
FEBS J. 2015 Jan;282(1):65-73. (PMID: 25303711)
Biochem Biophys Res Commun. 2016 Sep 2;477(4):700-705. (PMID: 27363332)
J Biol Chem. 1996 Nov 22;271(47):29525-8. (PMID: 8939877)
CNS Neurol Disord Drug Targets. 2015;14(7):828-37. (PMID: 25801844)
Curr Alzheimer Res. 2005 Apr;2(2):131-6. (PMID: 15974909)
Trends Pharmacol Sci. 2018 Jan;39(1):49-58. (PMID: 29132916)
Curr Top Med Chem. 2011;11(12):1555-70. (PMID: 21510832)
Sci Rep. 2017 Jan 23;7:41051. (PMID: 28112214)
Neurology. 2005 May 10;64(9):1553-62. (PMID: 15883316)
J Neurotrauma. 2017 Sep 15;34(18):2609-2623. (PMID: 28095731)
Neuron. 2010 Sep 9;67(5):769-80. (PMID: 20826309)
J Biol Chem. 2008 Oct 31;283(44):29621-5. (PMID: 18650431)
Am J Alzheimers Dis Other Demen. 2012 Aug;27(5):296-300. (PMID: 22815077)
Neuropharmacology. 2016 Apr;103:57-68. (PMID: 26690893)
Neurology. 2008 May 6;70(19):1672-7. (PMID: 18458226)
J Alzheimers Dis. 2011;26(3):485-94. (PMID: 21694459)
Acta Neuropathol. 2015 Oct;130(4):487-99. (PMID: 26363791)
Neurobiol Aging. 2015 May;36(5):1792-807. (PMID: 25771396)
Biochemistry. 2010 Apr 20;49(15):3261-72. (PMID: 20230062)
Front Cell Neurosci. 2018 Apr 27;12:114. (PMID: 29755324)
J Biol Chem. 2010 Nov 26;285(48):37405-14. (PMID: 20876579)
Brain Pathol. 2017 Jan;27(1):86-94. (PMID: 26919450)
Eur J Clin Pharmacol. 2000 Jun;56(3):247-50. (PMID: 10952480)
Mol Neurobiol. 2020 Dec;57(12):4961-4977. (PMID: 32820459)
PLoS One. 2010 May 11;5(5):e10549. (PMID: 20485502)
Acta Neuropathol. 2000 Feb;99(2):91-5. (PMID: 10672313)
Neuroscience. 2004;129(3):615-28. (PMID: 15541883)
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):13075-80. (PMID: 14566063)
Environ Sci Pollut Res Int. 2018 Aug;25(24):23909-23916. (PMID: 29881965)
Sci Transl Med. 2011 May 25;3(84):84ra44. (PMID: 21613623)
Neurobiol Stress. 2018 Sep 01;9:105-112. (PMID: 30450376)
Drug Metab Rev. 2014 May;46(2):207-23. (PMID: 24495298)
Nat Neurosci. 2012 Jan 29;15(3):349-57. (PMID: 22286176)
Science. 2002 Jul 19;297(5580):353-6. (PMID: 12130773)
Curr Neuropharmacol. 2009 Mar;7(1):1-8. (PMID: 19721814)
Nat Struct Mol Biol. 2010 May;17(5):561-7. (PMID: 20383142)
Neurosci Biobehav Rev. 2019 Jan;96:302-315. (PMID: 30513312)
J Alzheimers Dis. 2005 Feb;7(1):63-80. (PMID: 15750215)
Mol Cell Neurosci. 2012 Apr;49(4):423-9. (PMID: 22402435)
Alzheimers Dement. 2013 Jan;9(1):63-75.e2. (PMID: 23305823)
Mol Interv. 2008 Dec;8(6):268-73. (PMID: 19144897)
Biophys J. 2012 Aug 22;103(4):L27-9. (PMID: 22947946)
Int J Mol Sci. 2020 Jul 27;21(15):. (PMID: 32727084)
Neurology. 2003 Jul 8;61(1):46-54. (PMID: 12847155)
Nat Rev Neurol. 2010 Feb;6(2):108-19. (PMID: 20140000)
J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):13-7. (PMID: 18931004)
Front Pharmacol. 2019 Sep 12;10:1008. (PMID: 31572186)
N Engl J Med. 2010 Jan 28;362(4):329-44. (PMID: 20107219)
J Struct Biol. 2000 Jun;130(2-3):88-98. (PMID: 10940217)
J Neurosci. 1996 Dec 15;16(24):7910-9. (PMID: 8987819)
Nat Neurosci. 2016 Jan;19(1):55-64. (PMID: 26642089)
J Neurochem. 2007 Jul;102(2):420-33. (PMID: 17596213)
Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12. (PMID: 17245412)
Biosens Bioelectron. 2014 Apr 15;54:492-8. (PMID: 24321883)
Brain Res Bull. 2017 Jul;133:71-79. (PMID: 27545490)
Lancet Neurol. 2015 Apr;14(4):388-405. (PMID: 25792098)
Neural Regen Res. 2012 Feb 15;7(5):376-85. (PMID: 25774178)
EBioMedicine. 2017 Oct;24:93-101. (PMID: 28919280)
J Cell Biol. 2011 Oct 31;195(3):515-24. (PMID: 22024165)
J Intern Med. 2011 Jan;269(1):54-63. (PMID: 21158978)
Nat Chem Biol. 2011 Nov 20;8(1):93-101. (PMID: 22101602)
J Alzheimers Dis. 2010;19(4):1205-19. (PMID: 20308787)
Exp Neurol. 2013 Jan;239:133-8. (PMID: 23063604)
Cold Spring Harb Perspect Med. 2012 Feb;2(2):a006288. (PMID: 22355794)
Nat Rev Neurol. 2015 Aug;11(8):457-70. (PMID: 26195256)
Immun Ageing. 2013 May 11;10(1):18. (PMID: 23663286)
BMC Bioinformatics. 2011 Feb 15;12 Suppl 1:S28. (PMID: 21342558)
J Physiol. 2016 Aug 15;594(16):4565-79. (PMID: 26332795)
Environ Sci Pollut Res Int. 2020 Oct;27(30):37709-37717. (PMID: 32608003)
CNS Neurol Disord Drug Targets. 2014;13(9):1530-41. (PMID: 25106636)
J Biol Chem. 2007 Apr 6;282(14):10311-24. (PMID: 17284452)
Rom J Morphol Embryol. 2017;58(1):207-210. (PMID: 28523320)
J Neurosci. 2003 Jul 2;23(13):5531-5. (PMID: 12843253)
Nat Chem Biol. 2008 Mar;4(3):197-9. (PMID: 18223646)
Brain Res Bull. 2016 Sep;126(Pt 2):199-206. (PMID: 27133790)
Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):198-203. (PMID: 20505438)
Alzheimers Dement (N Y). 2017 Jan;3(1):65-73. (PMID: 28497107)
Brain Behav Immun. 2010 May;24(4):598-607. (PMID: 20060887)
ACS Chem Neurosci. 2014 Feb 19;5(2):83-92. (PMID: 24328060)
PLoS One. 2013;8(1):e54769. (PMID: 23382963)
Biophys Chem. 2013 Dec 1;182:30-43. (PMID: 23820236)
J Biol Chem. 2001 Jul 6;276(27):24540-8. (PMID: 11337485)
J Food Drug Anal. 2020 Jan;28(1):132-146. (PMID: 31883601)
J Neurochem. 2006 Jan;96(2):533-40. (PMID: 16336629)
J Mol Graph Model. 2019 Dec;93:107456. (PMID: 31581064)
Alzheimer Dis Assoc Disord. 2002 Oct-Dec;16(4):203-12. (PMID: 12468894)
Cell Mol Life Sci. 2009 Apr;66(8):1321-5. (PMID: 19266159)
Dev Neurobiol. 2018 Mar;78(3):340-347. (PMID: 29106038)
Curr Opin Drug Discov Devel. 2004 Sep;7(5):709-19. (PMID: 15503873)
FASEB J. 2011 Feb;25(2):775-84. (PMID: 21059748)
Nat Med. 2002 Nov;8(11):1263-9. (PMID: 12379850)
Ther Adv Neurol Disord. 2013 Jan;6(1):19-33. (PMID: 23277790)
Oxid Med Cell Longev. 2017;2017:2525967. (PMID: 28785371)
Biochim Biophys Acta. 2007 Aug;1768(8):1966-75. (PMID: 17553456)
J Biol Chem. 2006 Feb 17;281(7):4292-9. (PMID: 16361260)
Immunotargets Ther. 2015 Jan 08;4:27-34. (PMID: 27471709)
Brain Res Bull. 2017 Jul;133:88-96. (PMID: 27316747)
Mol Neurobiol. 2015 Oct;52(2):1034-42. (PMID: 26055231)
J Pept Res. 2002 Jul;60(1):37-55. (PMID: 12081625)
J Neurosci. 2003 Apr 1;23(7):2665-74. (PMID: 12684452)
EMBO Rep. 2000 Dec;1(6):530-5. (PMID: 11263499)
Pharmacol Rep. 2016 Feb;68(1):127-38. (PMID: 26721364)
Biochemistry. 1999 Mar 23;38(12):3570-8. (PMID: 10090743)
Peptides. 2002 Dec;23(12):2223-6. (PMID: 12535702)
Trends Immunol. 2008 Aug;29(8):357-65. (PMID: 18599350)
Brain Res Bull. 2019 Mar;146:171-184. (PMID: 30634016)
J Neurosci. 2009 Aug 26;29(34):10582-7. (PMID: 19710311)
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11213-8. (PMID: 8855335)
Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10573-7. (PMID: 7504270)
Ann Neurol. 2005 Sep;58(3):430-5. (PMID: 16130106)
Nature. 2011 Apr 14;472(7342):226-9. (PMID: 21451522)
Neuropharmacology. 2015 Sep;96(Pt B):255-62. (PMID: 25514383)
Neurotherapeutics. 2013 Jul;10(3):429-39. (PMID: 23670234)
J Neurosci Res. 2003 Jun 1;72(5):603-12. (PMID: 12749025)
Biochemistry. 2008 Feb 19;47(7):1984-92. (PMID: 18189413)
Cell Calcium. 2003 Oct-Nov;34(4-5):385-97. (PMID: 12909083)
Neurobiol Dis. 2018 May;113:1-10. (PMID: 29414379)
Arch Biochem Biophys. 2012 Oct 15;526(2):132-8. (PMID: 22475448)
Genome Med. 2015 Oct 20;7:106. (PMID: 26482651)
J Biol Chem. 1996 Apr 12;271(15):8545-8. (PMID: 8621479)
J Enzyme Inhib Med Chem. 2011 Oct;26(5):643-8. (PMID: 21222511)
Arch Neurol. 2008 Jul;65(7):896-905. (PMID: 18474729)
EMBO Rep. 2003 Dec;4(12):1190-6. (PMID: 14618158)
Aging (Albany NY). 2011 Jan;3(1):14-6. (PMID: 21248377)
J Biol Chem. 2006 Aug 25;281(34):24566-74. (PMID: 16787929)
J Biol Chem. 2008 Oct 31;283(44):29615-9. (PMID: 18650430)
Proc Natl Acad Sci U S A. 2006 May 23;103(21):8215-20. (PMID: 16698938)
Biomaterials. 2020 Oct;255:120165. (PMID: 32540759)
J Mol Med (Berl). 1995 Sep;73(9):465-71. (PMID: 8528750)
Biochemistry. 2004 Nov 16;43(45):14454-62. (PMID: 15533050)
Acc Chem Res. 2014 Aug 19;47(8):2397-404. (PMID: 25029558)
Contributed Indexing :
Keywords: Alzheimer’s disease (AD); amyloid beta (Aβ) cascade; amyloid precursor protein; immune response; toxic oligomers
Substance Nomenclature :
0 (Amyloid beta-Peptides)
0 (Amyloid beta-Protein Precursor)
0 (Protein Aggregates)
Entry Date(s) :
Date Created: 20201014 Date Completed: 20210226 Latest Revision: 20210226
Update Code :
20210309
PubMed Central ID :
PMC7589257
DOI :
10.3390/ijms21207443
PMID :
33050199
Czasopismo naukowe
One of the most commonly occurring neurodegenerative disorders, Alzheimer's disease (AD), encompasses the loss of cognitive and memory potential, impaired learning, dementia and behavioral defects, and has been prevalent since the 1900s. The accelerating occurrence of AD is expected to reach 65.7 million by 2030. The disease results in neural atrophy and disrupted inter-neuronal connections. Amongst multiple AD pathogenesis hypotheses, the amyloid beta (Aβ) cascade is the most relevant and accepted form of the hypothesis, which suggests that Aβ monomers are formed as a result of the cleavage of amyloid precursor protein (APP), followed by the conversion of these monomers to toxic oligomers, which in turn develop β-sheets, fibrils and plaques. The review targets the events in the amyloid hypothesis and elaborates suitable therapeutic agents that function by hindering the steps of plaque formation and lowering Aβ levels in the brain. The authors discuss treatment possibilities, including the inhibition of β- and γ-secretase-mediated enzymatic cleavage of APP, the immune response generating active immunotherapy and passive immunotherapeutic approaches targeting monoclonal antibodies towards Aβ aggregates, the removal of amyloid aggregates by the activation of enzymatic pathways or the regulation of Aβ circulation, glucagon-like peptide-1 (GLP-1)-mediated curbed accumulation and the neurotoxic potential of Aβ aggregates, bapineuzumab-mediated vascular permeability alterations, statin-mediated Aβ peptide degradation, the potential role of ibuprofen and the significance of natural drugs and dyes in hindering the amyloid cascade events. Thus, the authors aim to highlight the treatment perspective, targeting the amyloid hypothesis, while simultaneously emphasizing the need to conduct further investigations, in order to provide an opportunity to neurologists to develop novel and reliable treatment therapies for the retardation of AD progression.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies